CervoMed

Q3 2025 Q2 2025 Q1 2025 Q4 2024 +3.20%Q3 2024 -7.58%Q2 2024 +32.98%Q1 2024 -1.38%Q4 2023 -4.89%Q3 2023 -2.64%Q2 2023 -1.05%Q1 2023 -5.42%Q4 2022 -8.73%Q3 2022 +21.45%Q2 2022 -2.00%Q1 2022 +18.57%Q4 2021 -3.70%Q3 2021 -6.67%Q2 2021 -7.02%Q1 2021 0.00%Q4 2020 +4.90%Q3 2020 -10.13%Q2 2020 -0.91%Q1 2020 +39.34%Q4 2019 -8.82%Q3 2019 -27.63%Q2 2019 -0.92%Q1 2019 -4.87%Q4 2018 +3.83%Q3 2018 0.00%Q2 2018 +2.78%Q1 2018 -3.64%Q4 2017 -3.64%Q3 2017 -3.65%Q2 2017 -7.74%Q1 2017 -0.56%Q4 2016 -0.56%Q3 2016 -3.81%Q2 2016 0.00%Q1 2016 +11.11%Q4 2015 -6.36%Q3 2015 -9.09%Q2 2015 +1.21%Q1 2015 -2.00%Q4 2014 -7.14%Q3 2014 -1.11%Q2 2014 +4.50%Q1 2014 -3.23%Q4 2013 0.00%Q3 2013 0.00%Q2 2013 0.00%Q1 2013 0.00%Q4 2012 +18.75%Q3 2012 +4.76%Q2 2012 -2.56%Q1 2012 0.00%Q4 2011 +8.00%Q3 2011 -11.48%Q2 2011 +7.14%Q1 2011 +5.45%Q4 2010 +1.56%Q3 2010 +19.05%Q2 2010 -12.04%Q1 2010 0.00%

Nov 14, 2022

•

Sep 30, 2022

CervoMed Q3 2022 Earnings Report

Provided an update on the strategic opportunities and its 2022 annual meeting of stockholders.

Key Takeaways

Diffusion Pharmaceuticals is actively pursuing a strategy to deliver stockholder value, including a possible sale, merger, or recapitalization. The company is in active bidding stage but the Board rejected an unsolicited offer from a LifeSci Capital client as inadequate, leading to a proxy contest.

Diffusion is evaluating strategic opportunities to enhance stockholder value.

The company is in the active bidding stage and encouraged by the response to the Strategic Review Process.

The Board rejected an unsolicited offer from a LifeSci Capital client.

LifeSci commenced a proxy contest for control of the Diffusion Board.

Previous year: $40.3M

-83.7%